DARMSTADT, GERMANY

Merck, a leading science and technology company, today launched its AIDDISON™ drug discovery software, the first software-as-a-service platform that bridges the gap between virtual molecule design and real-world manufacturability through SynthiaTM retrosynthesis software application programing interface (API) integration. It combines generative AI, machine learning and computer-aided drug-design to speed up drug development. Trained on more than…

Reduces process development time by an estimated 40 percent Enables biopharmaceutical companies to increase the speed to clinical manufacturing Adds to company’s best-in-class VirusExpress® Lentiviral Production Platform Merck, a leading science and technology company, has launched the VirusExpress® 293 Adeno-Associated Virus (AAV) Production Platform, making it one of the first CDMOs and technology-developers to provide a full viral…

– Merck’s unique technology, ChetoSensar™, gives new promise to ADCs by alleviating solubility challenges  – New DOLCORE™ platform increases speed-to-market by up to a year – Expanded ADC clinical manufacturing facility drives next generation ADCs, building on company’s 15 years of ADC Contract Development Manufacturing Organization (CDMO) experience – Reinforces company’s ambition to accelerate growth…

Expansion in Carlsbad, California, USA, doubles production capacity to support commercialization and industrialization of viral vectors Investment serves customers in addressing larger patient populations with new curative treatments Enables suspension production of viral vectors up to 1,000-liter scale Project adds to company’s ambition to accelerate growth through investments in “Big 3” businesses, which includes plans…